Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Buy rating and announces Price Target of $2.
Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Buy rating and announces Price Target of $2.